A segmental deletion resulting in DNAJB1-PRKACA gene fusion is now recognized as the signature genetic event of fibrolamellar hepatocellular carcinoma (FL-HCC), a rare but lethal liver cancer that primarily affects adolescents and young adults. Here, we implement CRISPR/Cas9 genome editing and transposon-mediated somatic gene transfer to demonstrate that expression of both the endogenous fusion protein or a chimeric cDNA leads to the formation of indolent liver tumors in mice that closely resemble human FL-HCC. Notably, overexpression of the wild type PRKACA was unable to fully recapitulate the oncogenic activity of DNAJB1-PRKACA, implying that FL-HCC does not simply result from enhanced PRKACA expression. Tumorigenesis was significantly enhanced by genetic activation of β-catenin, an observation supported by evidence of recurrent Wnt pathway mutations in human FL-HCC, as well as treatment with hepatotoxin 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), which causes tissue injury, inflammation and fibrosis. Our study validates the DNAJB1-PRKACA fusion kinase as an oncogenic driver and candidate drug target for FL-HCC. Practical and scalable mouse models of this disease serve as a resource to further explore tumor development and treatment.
Introduction
FL-HCC ubiquitously harbors a ~400kb deletion on chromosome 19 that produces an in-frame fusion of the DnaJ heat shock protein family member B1 (DNAJB1) and protein kinase cAMP-activated catalytic subunit alpha (PRKACA) (Fig. S1A) (1, 2) . DNAJB1 encodes a subunit of the heat shock factor 40 (HSP40) complex, which activates the ATPase of HSP70 and serves as a molecular chaperone that can be induced by an array of environmental stresses (3) . PRKACA encodes a catalytic subunit of protein kinase A (PKA), which resides in the cytoplasm in an inactive tetrameric complex with PKA C-β and two regulatory subunits of the PKA holoenzyme (4) . Activation of GPCRs leads to cAMP-dependent dissociation of PKA regulatory and catalytic subunits and subsequent phosphorylation of a panoply of cellular substrates (4) . The crystal structure of the DNAJB1-PRKACA fusion protein shows that the catalytic site, regulatory subunit binding and anchoring protein binding remain similar to the wild type PRKACA (5) .
Beyond the presence of DNAJB1-PRKACA fusions, FL-HCC tumorigenesis is poorly understood. Few, if any, other significantly recurrent mutated genes have been described (6, 7) . While copy number alterations have been observed, they do not directly implicate any additional known oncogenes or tumor suppressors (7) . Also, unlike liver cancer in older adults, FL-HCC is not associated with any known etiological risk factors such as alcoholism, chronic hepatitis infection, or liver flukes (8) .
Currently, FL-HCC is diagnosed histologically, described as large cells with granular eosinophilic cytoplasm, vesiculated nuclei, and large nucleoli. Ultrastructural studies observe a hyperaccumulation of mitochondria and abundant endoplasmic reticulum (9) . While young age and lack of chronic liver disease are suggestive of FL-HCC, classic HCC can also occur in young patients and misdiagnosis is common (10) . Based on the biological sensitivity and specificity of the presence the DNAJB1-PRKACA fusion, its detection will likely become considered critical for diagnosis of FL-HCC (2) .
Surgical resection is currently the primary treatment for FL-HCC patients. Although often described as a relatively indolent disease, a high rate of recurrence represents a major clinical challenge (11) and the 5-year survival rate is 34% (12) . There is no evidence of survival benefit from adjuvant chemotherapy or any systemic treatment applicable to classic HCC (13) . The unique demographics and genetics of FL-HCC suggest that these patients should be treated differently than those harboring HCC, The segmental deletion that results in the DNAJB1-PRKACA gene fusion entails heterozygous loss of 7 other coding genes, with unknown functional contribution. In other contexts, such deletions can contribute to tumorigenesis directly through attenuating the function of haploinsufficient tumor suppressors (23) . To determine whether the DNAJB1-PRKACA fusion is sufficient to drive tumorigenesis and, if so, whether the simple overexpression of the wild-type PRKACA gene could recapitulate this effect, we used hydrodynamic injection to deliver a transposon expressing the human DNAJB1-PRKACA fusion cDNA or a full length wild-type PRKACA cDNA. Co-transfection of sleeping beauty transposase ("SBase") with a transposon construct allows for stable integration and constitutive expression of the cDNA in the absence of insertional mutagenesis following clearance of the non-integrating transposase, permitting sustained overexpression of the fusion protein that mimics the high levels in human tumors (1) (Fig. 2A) .
Although expression and protein stability are similar between the DNAJB1-PRKACA fusion protein and full-length WT PRKACA, and overexpression of wild type PRKACA was produced some changes to hepatocyte histology, it did not trigger the formation of lethal tumors (Fig. 2B-D) . However, following delivery of the DNAJB1-PRKACA cDNA, we observed tumors with similar kinetics, penetrance, and morphology as CRISPR-driven murine FL-HCC (Fig. 2B,C,E) . Again, a spectrum of histological findings supported the similarity between these lesions and human FL-HCC ( Fig. 1,2) , including the presence of large, often multi-nucleated, tumor cells with granular, eosinophilic cytoplasm and prominent nucleoli (Fig. 2F) . Cholestasis and distinctive cytoplasmic inclusions (pale bodies) were also seen (Fig.  2F) . Pale bodies and hyaline bodies are each present in about half of human FL-HCC cases (8) . These results imply that the DNAJB1 portion of the fusion contributes to disease beyond facilitating overexpression of PRKACA that the chromosome 19 deletion event is dispensable for oncogenesis.
Histological and structural features of murine FL-HCC.
To explore which disease-associated phenotypes can be directly attributed to the DNAJB1-PRKACA fusion in greater detail, we performed additional histological characterization of murine FL-HCC tumors. Ultrastructural analysis by electron microscopy (EM) revealed numerous features of FL-HCC. With respect to adjacent normal hepatocytes, which were often compressed at the tumor margins, tumor cells were enlarged with clumped heterochromatin (Fig. 3A-D, S2A) . Reminiscent of an FL-HCC-specific phenotype identified in previous studies of the human disease (8, 9, 24) , murine FL-HCC tumor cells contain strikingly high numbers of mitochondria with atypical appearance and abundant endoplasmic reticulum (yellow arrows, Fig. 3B ,E,F, S2E-H). The mitochondria were round to oval and homogeneous without obvious cristae and numerous megamitochrondria were observed. Mitochondria were surrounded by a rich accumulation of rough endoplasmic reticulum (red arrows, Fig. 3E-F,S2 ), but little smooth endoplasmic reticulum.
The cell-of-origin of FL-HCC remains unidentified, but human cases have been described to express mixed lineage markers (25, 26) . The mouse tumors appear to stain positive for hepatocyte markers HNF4A and HNF1A, with some tumor cells showing reduced expression, consistent with reduced hepatocyte lineage commitment (Fig. S3A,B) . The tumor cells are negative for biliary markers CK7 and CK19 and negative for CD68 (Fig. S3C-F) .
Unexpected observations including occasional necrotic cells and abnormal tumor-associated vessels were seen (Fig. 3B) . Throughout the tumor, cells had moderate to severe perinuclear aggregates of lipofuscin, a stress-related pigment that was also seen in the cytoplasm (Fig. 3D,E) . Tumor cell-cell margins were indistinct and cell-cell junctions were either simple or not obvious (Fig. S2A,B) , potentially indicative of decreased cell adhesion. As additional evidence of decreased cell-cell adhesion, membranous E-cadherin expression was reduced (Fig. 3G) . There is also a remarkable loss of cell polarity, indicated by a loss of synchronized glycogen storage amongst neighboring hepatocytes (Fig.  3G) . Elevated membranous β-catenin was seen, as was known PKA phosphorylation site (27) phospho-β-catenin S675 (Fig. 3G, Fig. S7 ). However, nuclear β-catenin staining was not appreciable in tumor samples.
Transcriptional profiling of murine FL-HCC confirms similarities to the human disease and suggests processes linked to tumorigeneis.
Murine FL-HCC tumors and control liver tissue were transcriptionally profiled by RNA-Seq (Supplementary Table 1 ). Reads that cross the junction were observed, confirming expression of the fusion (Fig. 4A) . Principal component analysis demonstrated that the vast majority of the variance described the differences between tumor and normal samples (Fig. 4B) . A total of 5710 genes were significantly differentially expressed between tumor and normal tissue (Supplementary Table 2) . A focused analysis to investigate the similarity between mouse and human tumors was evaluated in two ways. First, single sample gene set enrichment analysis (ssGSEA) (28) using FL-HCC expression signatures from three independent published studies (7, 10, 29) was used to confirm that genes differentially expressed in human tumors were, in aggregate, significantly enriched in our murine tumors (Fig. 4C) . Second, a supervised analysis of curated functional gene sets previously reported as enriched in FL-HCC (29) were consistent with murine tumor expression data (Fig. S4A) . These results provide an unbiased analysis that classifies the murine model as FL-HCC.
This analysis also identified other biological and molecular features that are consistent with previous observations in human tumors. Global analysis of differentially expressed genes using GSEA revealed expression patterns suggesting biological processes associated with transformation ( Fig. 4D,E,  Supplementary Table 3) . For example, cell cycle and DNA biosynthesis gene sets, and specifically Cdk1, Gins2, and Cenpa, were highly upregulated in the experimental tumors (Fig. 4D,E) , which also showed alterations in mitogenic signaling genes such as downregulation of Deptor (a negative regulator of mTORC1 also decreased in human tumors), as well as upregulation of the RTK ligands Egf, Nrg2, and Ereg was observed in murine tumors (29) (Fig. S4E) . Supporting the notion that dedifferentiation is a feature of DNAJB1-PRKACA driven transformation, we observed downregulation of hepatocyte lineage markers and upregulation of some neuroendocrine markers (Fig. 4D, S4G) , as has been observed in human FL-HCC (29) . GSEA further showed downregulation of epithelial cell fate commitment, bile acid biosynthesis, liver specific genes, and xenobiotic metabolism and upregulation of a teratoma-associated gene set (Fig. 4E) . Similarly, hepatocyte gene expression is linked to distinct specialized zones (30) , were universally lost, further supporting a role for the loss of cell lineage identity in FL-HCC development (Fig.  S4H) .
Our analysis also suggested yet other biological processes that may be relevant to FL-HCC pathogenesis that have not been previously appreciated. Cdh1/E-cadherin as well as cell adhesion and desmosomes gene sets were downregulated, reinforcing histological and ultrastructural findings consistent with decreased cell-cell adhesion in murine FL-HCC (Fig. 4D,E) . Lastly, reaction to oxidative stress is indicated by the upregulation of enzymes involved in detoxifying reactive oxygen species (e.g. Nqo1, Gpx3, Gpx4, and Acox1) (Fig. 4D,S4F ). The accumulation of mitochondria can be driven by oxidative stress (32) , and interestingly, all detected transcripts encoded by the mitochondrial genome trended towards mild upregulation, consistent with hyperaccumulation of mitochondria seen by EM (Fig.  S4B) . Oxidative stress may also be related to the induction of inflammasome-associated genes ( Fig. 4E ) and the accumulation of lipofuscin ( Fig. 3F) (33, 34) , potentially helping to reconcile the elevated cell cycle rate with the indolent phenotype and growth rate of the tumors. It is possible that the kinetics of the tumors might indicate the requirement of secondary spontaneous genetic alterations for tumorigenesis, but copy number profiling by low-pass whole genome sequencing of a murine FL-HCC shows at least no significant genomic amplifications or deletions (Fig. S4A) .
WNT pathway cooperates with fusion to accelerate FL-HCC tumorigenesis
To further understand FL-HCC tumorigenesis, and to address the long latency of the single hit models, we investigated additional factors that could accelerate disease. We queried the MSK-IMPACT collection of clinical sequencing data, which contains targeted sequencing data of over 18,000 cancer patients (35) . Eighteen liver cancer patients (age 18-36) whose tumors harbored the DNAJB1-PRKACA fusion were identified (Fig. 5A) . As expected, the fusion was not detected in any liver cancer patient over the age of 36 (0/414 patients) or in any non-liver cancer patient (0/18,367 patients), confirming the remarkable specificity of the DNAJB1-PRKACA fusion to liver oncogenesis (Fig. S6A) . While HCC and intrahepatic cholangiocarcinoma (ICC) share several mutations among the most commonly mutated genes of each disease, none of these have been previously described in FL-HCC. Surprisingly, we noted previously unreported recurrent mutations in the Wnt pathway in human FL-HCC (Fig. 5A,B) . The MSK-IMPACT cohort contains 3/18 (17%) cases of FL-HCC with CTNNB1 or APC mutation (age 18-21 years old).
In parallel, candidate drivers of liver cancer were evaluated for their ability to synergize with DNAJB1-PRKACA to transform hepatocytes. Neither transposon based delivery of MYC, AKT myr , NOTCH ICD , YAP S127A , Fgf15, Il10, Il18, Tgfb1, nor Cre-loxP-or CRISPR-mediated knockout of p19 ARF , Pten, Prkar1a, Rb1, Cdkn1b, and Tsc2 , showed any cooperative effects (data not shown). However, among interrogated genes, β-catenin (using a transposon encoding CTNNB1 T41A cDNA) uniquely cooperated with DNAJB1-PRKACA, which we explored further. Of note, the CTNNB1 T41A is the same allele that occurred in a primary FL-HCC and its corresponding brain metastasis (Fig. 5B, Fig. S6B ). Both pairs of tandem guide CRISPRs, as well as transposon delivery of fusion cDNA, synergized with transposon delivery of stabilized β-catenin, increasing penetrance and reducing latency of the model (Fig.  5C,D) . In all cases, the histology of the resulting tumors matched the single hit models, though some features (e.g. cell size) were exaggerated (Fig. 5E) . The acceleration of the model by Wnt signaling was further validated by the combination of DNAJB1-PRKACA cDNA and disruption of Apc using CRISPR, which yielded tumors with a similar phenotype (Fig. S7) . While expression of the DNAJB1-PRKACA fusion alone led to increased membranous β-catenin, and phosphorylation of β-catenin at PKA phosphorylation site S675, expression of the canonical Wnt target AXIN2 was observed only in samples with genetic manipulation of the Wnt pathway (Fig. S7 ). To further demonstrate the oncogenecity of the model, we recovered tumor tissue from a CRISPR.1 and CTNNB1 expressing tumor Addition of β-catenin did not instigate chromosomal instability, as had previously been observed in other cancer types (36, 37) (Fig. S4) . Hence, genetic lesions that deregulate Wnt signaling can occur in the human disease and provide a unique second hit pathway that cooperates with DNAJB1-PRKACA to accelerate FL-HCC.
Inflammatory and fibrotic agent DDC enhances FL-HCC tumorigenesis
In contrast to adult HCC, FL-HCC occurs in young patients without chronic liver disease (8) . Nevertheless, given that the DNAJB1-PRKACA fusion was insufficient to generate the eponymous fibrosis associated with the human disease, we wondered whether experimental strategies to induce fibrosis might facilitate the optimal growth of murine FL-HCC. The administration of the hepatotoxin 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) causes oxidative liver damage, cell death in periportal hepatocytes, atypical ductal expansion of progenitor cells, and ultimately, fibrosis (38) , and can accelerate HCC tumorigenesis by specific oncogenic events (39, 40) . Consistent with published results, mice treated with a 0.1% DDC-containing diet develop hepatomegaly, inflammation, and fibrosis with portal bridging by 8 weeks of treatment, but DDC alone does not generate tumors (38, 41) (Fig. 6A-C,S8) . DDC-fed mice in which the fusion or CTNNB1 alone was expressed formed clusters of tumor cells at an accelerated rate, and the combination of DDC, DNAJB1-PRKACA, and CTNNB1 together synergized to instigate faster tumor development and more aggressive disease (Fig. 6A,B) . The histology of the tumor cells themselves remained largely unchanged by DDC treatment, but as expected, the surrounding tissue acquired DDC-associated phenotypes associated with tissue regeneration following injury (Fig. 6C) . Surprisingly the morbidity of the combination often preceded the establishment of significant fibrosis (Fig.  6C,S8) . Therefore, our data suggests that one or more factors in associated with the DDC-induced regenerative response can fuel murine FL-HCC. Regardless, the use of DDC enables the production of tumor-bearing mice at high penetrance and with short latency.
Tumorigenicity of DNAJB1-PRKACA is dependent on kinase domain.
To illustrate the potential of a rapid and robust model of FL-HCC, we used the above methods to address whether the kinase activity of the DNAJB1-PRKACA fusion is essential for its ability to drive tumorigenesis-a prerequisite for rationalizing the use of small molecule inhibitors targeting the PRKACA kinase for treatment of FL-HCC. To this end, we produced a kinase dead version of the DNAJB1-PRKACA fusion harboring a mutation in the PRKACA component, equivalent to the previously described K72H mutation (42, 43) , and compared its oncogenic potential to the intact fusion cDNA, when combined with DDC and CTNNB1 T41A . At approximately 10 weeks post-injection, we sacrificed a cohort of animals and examined liver lesions. While clusters of neoplastic hepatocytes with classic FL-HCC morphology were observed in samples with an intact kinase domain, no such atypical hepatocytes were identified in require expensive and time-consuming breeding schemes. This approach allows for the synchronous generation of large cohorts of mice for survival and intervention studies. We anticipate that the systems described here will provide powerful platforms to further understand the biology of FL-HCC and empower drug discovery for a disease with severely limited treatment options that disproportionately affects young patients.
Materials and Methods

Vectors and cloning
One sgRNA was cloned into the px330 vector, which was a gift from Feng Zhang (Addgene plasmid # 42230) (52) , and a second U6-sgRNA cassette was inserted in the XbaI site with XbaI-NheI overhangs. As indicated, for other experiments (Fig. S1) , the lenti-CRISPR vector was a gift from David Sabatini (Addgene plasmid # 70662) (53) 
Animals and Treatments
Female, 8-to 10-week-old C57BL6/N mice were purchased from Envigo (East Millstone, NJ). All animal experiments were approved by the MSKCC Institutional Animal Care and Use Committee (protocol 11-06-011). For hydrodynamic tail-vein injection, a sterile 0.9% NaCl solution was prepared containing plasmid DNA of either 40μg CRISPR vector or 20μg transposon vector together with CMV-SB13 Transposase (1:5 molar ratio). Mice were injected into the lateral tail vein with a total volume corresponding to 10% of body weight (typically 2 ml for a 20g mouse) in 5-7 seconds (15, 54) . DDC treatment was accomplished by feeding mice a diet containing 0.1% DDC (Sigma-Aldrich, St. Louis, Missouri; Envigo, Madison, WI) until sacrifice (40) .
Electron Microscopy
Tissue was fixed in 4% glutaraldehyde and transferred to cold PBS until further processed. The tissues were post fixed in 1% osmium tetroxide in PBS. After washing in water, the tissue was stained with 2% aqueous uranyl acetate for ~2 h at 4°. Tissues were dehydrated through a series of acetones and propylene oxide and embedded in Epon. Ultrathin sections were deposited on grids and stained with uranyl acetate for 15 minutes and lead citrate for 5 minutes.
Immunohistochemistry and Immunofluorescence
Tissue was prepared for histology by fixing in 10% buffered formalin overnight then transferred to 70% ethanol until paraffin embedding and sectioning (IDEXX RADIL, Columbia, MO). Antigen retrieval was performed in a pressure cooker with Sodium Citrate buffer. Primary antibodies were incubated at 4°C overnight in blocking buffer. Sections were incubated with anti-rabbit ImmPRESS HRP-conjugated secondary antibodies (Vector Laboratories, #MP7401) and chromagen development performed using ImmPact DAB (Vector Laboratories, #SK4105). Stained slides were counterstained with Harrisʼ hematoxylin. Images of stained sections were acquired on a Zeiss Axioscope Imager Z.1 and an ORCA/ER CCD camera (Hamamatsu Photonics, Hamamatsu, Japan). Raw .tif files were processed using Photoshop CS5 software (Adobe Systems Inc., San Jose, CA) to adjust white balance.
RNAseq
Total RNA was isolated from frozen tissue using the RNeasy Mini Kit (Qiagen), quality control was performed on an Agilent BioAnalyzer, 500 ng of total RNA (RNA integrity number > 8) underwent polyA selection and Truseq library preparation according to instructions provided by Illumina (TruSeq RNA Sample Prep Kit v.2) with 6 cycles of PCR. Single-end, 75-bp sequencing was performed at the CSHL core facility. Approximately 8 million reads were acquired per sample. Resulting RNA-Seq data was analyzed as described previously (23) . Adaptor sequences were removed using Trimmomatic. RNA-seq reads were then aligned to the mouse genome (mm10) using STAR (55) with default parameters and genome-wide transcript counting was performed using subread to generate a count matrix (56, 57) . Differential expression analysis was performed by DESeq2 (58) . Genes were considered to be significantly differentially expressed if tumor/normal comparison was greater than 2-fold and FDRadjusted p value was less than 0.05.
Human-Murine mapping of orthologs was performed based on the Ensembl database accessed through the Biomart R/Bioconductor package (59) . Human fibrolamellar HCC signatures were set as genes with at least 2-fold and significant expression changes in fibrolamellar tumors with respect to normal. Human transcriptional profiling data was obtained from published studies (7, 29) , and the TCGA/Broad GDAC firehose using annotation from Dinh et al (10) . For comparison to human datasets and for gene set enrichment analysis, the ssGSEA method was implemented using the GSVA package within R (28) . The GSVA outputs were subsequently compared across groups using the limma package (60) . The C2, C3, C5, and Hallmark collections of gene sets from MSigDBv6.0 were queried (61).
Copy Number Profiling
Low-pass whole genome sequencing was used to determine tumor copy number profiles as described previously (23) . One microgram of DNA per sample was sonicated (17 W, 75 s) on an E220 sonicator (Covaris), prepared using standard Illumina library preparation, purified using AMPure XP magnetic beads (Beckman Coulter), PCR enriched, and sequenced on an Illumina HiSeq instrument in a multiplexed format. Sequencing reads per sample were mapped using Bowtie with PCR duplicates removed. Approximately 2.5 million uniquely mappable reads were further processed for copy number determination using the ʻvarbinʼ algorithm with 5,000 bins, allowing for a median resolution of approximately 600 kb after GC content normalization, segmentation and copy number estimation (62) .
Human Tumor Sequencing Data
The MSK-IMPACT sequencing data (35) were obtained from the MSKCC cBioPortal (63) (http://www.cbioportal.org). Of the 18 DNAJB1-PRKACA fusion cases, 14 were annotated as fibrolamellar HCC and 4 were annotated as HCC. We considered all DNAJB1-PRKACA positive liver cancers as FL-HCC, given the common of misdiagnosis of this rare cancer type (10), for which the presence of the DNAJB1-PRKACA should be considered diagnostic (2). Low-pass whole genome sequencing was performed and data was binned into 5000 segments for (A) a tumor generated by a transposon expressing DNAJB1-PRKACA and (B) a tumor generated by the combination of transposons expressing DNAJB1-PRKACA and CTNNB1. Fig. S5 . Gene expression of FL-HCC-associated gene sets of interest. (A) ssGSEA enrichment scores from mouse tumor differential expression (homologs converted to human genes) for gene sets significantly enriched in either upregulated or downregulated human gene expression data (29) (p=4. . (B) Gene expression for genes encoded by mitochondrial DNA. Gene expression of corresponding mouse and human (29) genes in the specified gene sets: (C) CREB targets (D) Wnt signaling pathway (E) GRB2 events in ERBB2 signaling (F) genes upregulated by ROS (G) Lineage specific genes including neuroendocrine markers (29) and (H) liver zone-specific genes (30) . Tandem guide CRISPR   14,650,000 14,200,000
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Human chr19 Figure 7 . Tumorigenicity of DNAJB1-PRKACA is dependent on kinase domain. DKK4  LEF1  FZD8  JAG2  JAG1  HEY1  DLL1  PPARD  CCND2  HDAC11  NKD1  TP53  NCSTN  KAT2A  NOTCH4  RBPJ  HDAC2  CUL1  NCOR2  PSEN2  CSNK1E  MAML1  AXIN1  TCF7  ADAM17  DVL2  PTCH1  CTNNB1  AXIN2  NUMB  FZD1  NOTCH1  HDAC5  MYC  SKP2  GNAI1  HEY2  WNT6  FRAT1  WNT5B   EREG  NRG2  EGF  ERBB2  CDK1  EGFR  KRAS  HRAS  GRB2  YWHAB  SOS1  ERBB4  NRAS  MAPK3  BTC  MAPK1  HBEGF  RAF1  MAP2K1  NRG1  NRG4   NQO1  PFKP  SRXN1  TXNRD1  GLRX  ABC1  PRDX4  GPX3  SOD2  GSR  PRDX1  ERCC2  NDUFS2  HMOX2  GLRX2  SBNO2  TXN  MGST1  PRDX6  NDUFA6  PPP2R5  OXSR1  NDUFB4  STK25  GCLM  FTL  SCAF4  CDKN2D  ATOX1  PRNP  FES  GCLC  HHEX  GPX4  MBP  PDLIM1  MSRA  LSP1  JUNB  TXNRD2  MPO  SOD1  CAT   NTS  CALCA  CPE  RGS17  UCHL1  SYP  NCAM1  PSMD4  AXIN2  CYP2E1  GLUL  CYP1A2  ARG1  ASS1  PCK1  SDHD  C2  ALB  IGFBP2  HAMP 
